GSK PLANS TO INCREASE DRUG SALES TO MIDDLE-INCOME COUNTRIES
GSK plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations, Bloomberg reports.
"Our strategy is to grow our business in middle income countries by increasing the volume of products we sell," CEO, Andrew Witty said. Extending GSK's flexible pricing programme for such nations would "improve the affordability of our medicines, increase access for patients with lower income levels and be profitable for GSK," he said.
Middle-income nations are "diverse in terms of economic status, demography and healthcare infrastructure which can vary significantly," Witty said, but did not identify individual countries. "Taking a single pricing approach would be difficult, inappropriate and inequitable," he added.